310 related articles for article (PubMed ID: 19729086)
41. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
[TBL] [Abstract][Full Text] [Related]
42. Strategies in the development of vaccines to prevent infections with group A streptococcus.
Good MF; Batzloff MR; Pandey M
Hum Vaccin Immunother; 2013 Nov; 9(11):2393-7. PubMed ID: 23863455
[TBL] [Abstract][Full Text] [Related]
43. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice.
Ma CQ; Li CH; Wang XR; Zeng RH; Yin XL; Feng HD; Wei L
Cell Mol Immunol; 2009 Feb; 6(1):73-7. PubMed ID: 19254483
[TBL] [Abstract][Full Text] [Related]
44. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate.
Guerino MT; Postol E; Demarchi LM; Martins CO; Mundel LR; Kalil J; Guilherme L
Vaccine; 2011 Oct; 29(46):8250-6. PubMed ID: 21907752
[TBL] [Abstract][Full Text] [Related]
45. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
Mansour NM; Abdelaziz SA
Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus.
Simerska P; Abdel-Aal AB; Fujita Y; Batzloff MR; Good MF; Toth I
Biopolymers; 2008; 90(5):611-6. PubMed ID: 18381625
[TBL] [Abstract][Full Text] [Related]
47. Development of conformational mimetics of conserved Streptococcus pyogenes minimal epitope as vaccine candidates.
Zhong W; Skwarczynski M; Toth I
Curr Drug Deliv; 2009 Oct; 6(5):520-7. PubMed ID: 19863488
[TBL] [Abstract][Full Text] [Related]
48. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
Schulze K; Medina E; Guzmán CA
Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
[TBL] [Abstract][Full Text] [Related]
49. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation.
Moyle PM; Olive C; Ho MF; Good MF; Toth I
J Med Chem; 2006 Oct; 49(21):6364-70. PubMed ID: 17034142
[TBL] [Abstract][Full Text] [Related]
50. M-protein-derived conformational peptide epitope vaccine candidate against Group A Streptococcus.
Skwarczynski M; Kamaruzaman KA; Srinivasan S; Zaman M; Lin IC; Batzloff MR; Good MF; Toth I
Curr Drug Deliv; 2013 Feb; 10(1):39-45. PubMed ID: 22998043
[TBL] [Abstract][Full Text] [Related]
51. Group A streptococcal M proteins: virulence factors and protective antigens.
Robinson JH; Kehoe MA
Immunol Today; 1992 Sep; 13(9):362-7. PubMed ID: 1281632
[TBL] [Abstract][Full Text] [Related]
52. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
53. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins.
Lei B; Liu M; Chesney GL; Musser JM
J Infect Dis; 2004 Jan; 189(1):79-89. PubMed ID: 14702157
[TBL] [Abstract][Full Text] [Related]
54. In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.
Nordström T; Malcolm J; Magor G; Good MF; Batzloff MR
Clin Vaccine Immunol; 2012 Dec; 19(12):1984-7. PubMed ID: 23081813
[TBL] [Abstract][Full Text] [Related]
55. Identification and assessment of new vaccine candidates for group A streptococcal infections.
McMillan DJ; Batzloff MR; Browning CL; Davies MR; Good MF; Sriprakash KS; Janulczyk R; Rasmussen M
Vaccine; 2004 Jul; 22(21-22):2783-90. PubMed ID: 15246612
[TBL] [Abstract][Full Text] [Related]
56. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development.
Smeesters PR; Mardulyn P; Vergison A; Leplae R; Van Melderen L
Vaccine; 2008 Oct; 26(46):5835-42. PubMed ID: 18789365
[TBL] [Abstract][Full Text] [Related]
57. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
Ozberk V; Pandey M; Good MF
Hum Vaccin Immunother; 2018; 14(8):2034-2052. PubMed ID: 29873591
[TBL] [Abstract][Full Text] [Related]
58. A vaccine against S. pyogenes: design and experimental immune response.
Guilherme L; Postol E; Freschi de Barros S; Higa F; Alencar R; Lastre M; Zayas C; Puschel CR; Silva WR; Sa-Rocha LC; Sa-Rocha VM; Pérez O; Kalil J
Methods; 2009 Dec; 49(4):316-21. PubMed ID: 19409999
[TBL] [Abstract][Full Text] [Related]
59. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
[TBL] [Abstract][Full Text] [Related]
60. Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.
Aranha MP; Penfound TA; Spencer JA; Agarwal R; Baudry J; Dale JB; Smith JC
J Biol Chem; 2020 Mar; 295(12):3826-3836. PubMed ID: 32029479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
